Literature DB >> 8349043

Inositol glycan phosphate derived from human erythrocyte acetylcholinesterase glycolipid anchor and inositol cyclic 1,2-phosphate antagonize glucagon activation of glycogen phosphorylase.

M A Deeg1, E P Brass, T L Rosenberry.   

Abstract

In this study we examine the hypothesis that an inositol glycan phosphate can act similarly to insulin on intact cells. The inositol glycan phosphate used in this study (glycan alpha) was isolated previously from the glycoinositol phospholipid anchor of human erythrocyte acetylcholinesterase and was shown to have the structure glycine-ethanolamine-PO4-Man-Man-(N,N-dimethylethanolamine-PO4)Man- (N,N-dimethyl)GlcN-inositol-PO4. The cellular response investigated was the glucagon-stimulated activation of glycogen phosphorylase in rat hepatocytes. When hepatocytes were incubated with 20 nM glucagon for 4 min, the ratio of phosphorylase a activity to total phosphorylase increased from a basal value of 0.49 +/- 0.02 to 0.82 +/- 0.03 (mean +/- SE, n = 15). Inclusion of either 100 nM insulin or 3-10 microM glycan alpha during the glucagon incubation significantly decreased the glucagon-stimulated activity ratio to 0.74 +/- 0.03 for either agent. Furthermore, hepatocyte preparations differed in their response to insulin and were divided into insulin-responsive and -resistant groups. Glycan alpha had a significant effect only in the insulin-responsive group for which the observed activity ratio for 10 microM glycan alpha plus glucagon (0.68 +/- 0.05) compared closely with that for insulin plus glucagon (0.70 +/- 0.04). For the insulin-resistant group, the activity ratio in the presence of 10 microM glycan alpha was 0.81 +/- 0.03, unchanged from the control with glucagon alone. Because glycan alpha contains an inositol phosphate group, the effect of inositol cyclic 1,2-phosphate on the glucagon-stimulated activity ratio was determined.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349043     DOI: 10.2337/diab.42.9.1318

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Glycosylphosphatidylinositol (GPI) hydrolysis by transforming growth factor-beta1 (TGF-beta1) as a potential early step in the inhibition of epithelial cell proliferation.

Authors:  P Bogdanowicz; J P Pujol
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  Signalling pathways of an insulin-mimetic phosphoinositolglycan-peptide in muscle and adipose tissue.

Authors:  A Kessler; G Müller; S Wied; A Crecelius; J Eckel
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

3.  Convergence and divergence of the signaling pathways for insulin and phosphoinositolglycans.

Authors:  G Müller; S Wied; C Piossek; A Bauer; J Bauer; W Frick
Journal:  Mol Med       Date:  1998-05       Impact factor: 6.354

4.  Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action.

Authors:  H K Wasner; S Weber; H J Partke; H Amini-Hadi-Kiashar
Journal:  Acta Diabetol       Date:  1994-12       Impact factor: 4.280

5.  ACTH stimulates the release of alkaline phosphatase through Gi-mediated activation of a phospholipase C and the release of inositol-phosphoglycan.

Authors:  Claudia N Martini; Silvia G Vaena de Avalos; María del Carmen Vila
Journal:  Mol Cell Biochem       Date:  2004-03       Impact factor: 3.396

6.  Stimulation of glycogen synthesis by insulin in human erythroleukemia cells requires the synthesis of glycosyl-phosphatidylinositol.

Authors:  D F Lazar; J J Knez; M E Medof; P Cuatrecasas; A R Saltiel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport.

Authors:  G Müller; E A Dearey; A Korndörfer; W Bandlow
Journal:  J Cell Biol       Date:  1994-09       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.